Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003638058 | SCV004456835 | pathogenic | MHC class II deficiency | 2023-04-09 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the RFX5 protein in which other variant(s) (p.Ser571Glnfs*22) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with RFX5-related conditions. This sequence change creates a premature translational stop signal (p.Pro337Hisfs*2) in the RFX5 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 280 amino acid(s) of the RFX5 protein. |